Key Highlights
- Partnership to expand molecular testing across European and UK markets.
- Focus on rapid, in-house cancer diagnosis using NGS liquid biopsy panels.
- Pillar’s oncoRevealTM LBx panels offer high sensitivity with results in less than three days.
- Scalable sequencing for economic value using Illumina NextSeq™.
Source: PR Newswire
Notable Quotes
- “Access to cost-effective, easy-to-use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally.” — Dan Harma, Chief Commercial Officer at Pillar Biosciences
- “We are committed to expanding global patient access to biomarker testing, and decentralized NGS solutions are key to this strategy.” — John Longshore, Head of Scientific Affairs, Global Oncology Diagnostics at AstraZeneca
SoHC's Take
This strategic partnership between Pillar Biosciences and AstraZeneca is a significant development in cancer diagnostics, especially in the European and UK markets. The ability to offer rapid and scalable Next Generation Sequencing (NGS) liquid biopsy tumor profiling empowers local laboratories to perform complex cancer diagnostics in-house. By reducing turnaround times from weeks to just a few days, Pillar’s oncoRevealTM LBx panels not only increase efficiency but also enhance clinical decision-making. This collaboration highlights the importance of decentralized testing in improving global access to precision oncology treatments.
Heading
Key Highlights 28% reductionin documentation time for care teams20% increasein patient engagement through automated outreachAI Agentsmanage SMS/voice outreach, scheduling, and ...
Key Highlights Warner Roberts appointed as Calibrate’s Chief Commercial OfficerWill lead commercial strategy to scale workplace obesity solutionsCalibrate members report ...
Key Highlights Fully integratedwith Castlight’s healthcare benefits app 24/7 on-demand carevia chat, video, and voice High-quality carefor common conditions delivered ...
Episode Details: Join us on the latest episode, hosted by Jared S. Taylor! Our Guest: Peter Donnelly, CEO & Co-Founder ...
In this five-part fireside chat, Dr. Jim Bonnette breaks down the real-world challenges holding health plans back—from fragmented vendor strategies ...
Key Highlights $47M oversubscribed funding round led by HealthQuest CapitalDeployed in 70+ health systems, including AdventHealth and Bon Secours Mercy ...
